Valuation: Guided Therapeutics, Inc.

Market Cap 1.4Cr 1.25Cr 1.15Cr 1.04Cr 1.95Cr 132.63Cr 1.99Cr 14Cr 5.51Cr 70Cr 5.24Cr 5.13Cr 220.01Cr P/E 2024
-3x
P/E 2025 -12.7x
Enterprise Value 1.68Cr 1.51Cr 1.39Cr 1.26Cr 2.35Cr 159.93Cr 2.39Cr 17Cr 6.64Cr 84Cr 6.32Cr 6.19Cr 265.31Cr EV / Sales 2024
1,649x
EV / Sales 2025 64.4x
Free-Float
63.48%
Yield 2024 *
-
Yield 2025 -
09/09 Guided Therapeutics, Inc. and Türkiye Ministry of Health Reach Collaborative Agreement for Primary Screening Test for Cervical Cancer CI
13/08 Guided Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
15/07 Guided Therapeutics, Inc. Announces New Agreement With Yuanshuo Medical Instruments Corporation CI
16/06 Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA CI
15/05 Guided Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
31/03 Guided Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
31/03 Guided Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
18/12 Guided Therapeutics, Inc. Announces Preliminary Findings from Its FDA Pivotal Clinical Trial CI
11/12 Guided Therapeutics, Inc. Receives $88,000 Payment as Third Installment of $700,000 Purchase Order with Chinese Distributor CI
19/11 Guided Therapeutics Inks Initial $200,000 Deal with New Distribution Partner Yuanshuo Medical Instruments Corporation CI
14/11 Guided Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
19/25/19 Guided Therapeutics, Inc. Receives $70,000 from New Chinese Distribution Partner That Provides Products for 2 Million Annual Cervical Cancer Screenings CI
15/25/15 Guided Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
1 week+34.71%
Current month-7.62%
1 month+14.50%
3 months-23.67%
6 months+14.50%
Current year-57.59%
1 week 0.13
Extreme 0.1319
0.23
1 month 0.13
Extreme 0.1319
0.24
Current year 0.13
Extreme 0.1319
0.54
1 year 0.13
Extreme 0.1319
0.54
3 years 0.06
Extreme 0.064
0.54
5 years 0.06
Extreme 0.062
0.78
10 years 0.02
Extreme 0.0206
3,200
Manager TitleAgeSince
Chief Executive Officer 70 06/03/2023
Chief Tech/Sci/R&D Officer 70 02/12/2010
Director TitleAgeSince
Director/Board Member 70 01/12/2016
Director/Board Member 76 10/04/2006
Chairman 67 01/10/2013
Date Insider Type Main position Quantity % Market Cap. Importance
10/03/26 Free

Chairman

1,10,000 0.1316%
10/03/26 Others

Director

4,66,991 0.5586%
10/03/26 Free

Director

1,10,000 0.1316%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+34.71%-0.43%+37.13% 1.4Cr
-1.86%+3.20%+25.02%+60.18% 26TCr
-2.01%+1.09%+8.35%+25.88% 17TCr
-3.74%-4.43%-18.44%+67.23% 16TCr
-1.77%-8.24%-58.31%-16.23% 6.19TCr
-2.67%+3.64%+10.58%+48.03% 5.44TCr
0.00%+2.46%-11.97%-6.29% 5.33TCr
-3.42%+1.31%+22.30%+73.30% 5.11TCr
+0.89%-3.43%+9.45%+63.95% 5.02TCr
-3.85%+1.72%+34.59%+94.97% 4.72TCr
Average -1.85%+1.52%+2.11%+44.81% 9.03TCr
Weighted average by Cap. -2.18%+2.44%+5.16%+47.93%

Financials

2024 2025
Net sales 7T 6.27T 5.77T 5.23T 9.77T 7L 9.95T 68.77T 27.61T 3L 26.27T 25.71T 11.03L 8L 7L 6L 6L 10.7L 7.28Cr 10.9L 75.35L 30.25L 3.83Cr 28.78L 28.17L 12Cr
Net income -24.17L -21.65L -19.91L -18.04L -33.72L -23Cr -34.36L -2.37Cr -95.32L -12Cr -90.71L -88.78L -38Cr -31.96L -28.62L -26.33L -23.86L -44.59L -30Cr -45.43L -3.14Cr -1.26Cr -16Cr -1.2Cr -1.17Cr -50Cr
Net Debt 17.71L 15.86L 14.59L 13.22L 24.71L 17Cr 25.17L 1.74Cr 69.84L 8.85Cr 66.46L 65.05L 28Cr 28.76L 25.76L 23.69L 21.47L 40.13L 27Cr 40.88L 2.83Cr 1.13Cr 14Cr 1.08Cr 1.06Cr 45Cr
Projected Income Statement - Annual - Guided Therapeutics, Inc.
Logo Guided Therapeutics, Inc.
Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Company’s primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.
Employees
3
Date Price Change Volume
29/26/29 $0.1447 -1.69% 1,000
28/26/28 $0.1472 +1.48% 1,951
27/26/27 $0.1450 +9.95% 1,127
26/26/26 $0.1319 -9.03% 1,003
23/26/23 $0.1450 -14.71% 10,272
  1. Stock Market
  2. Stocks
  3. GTHP Stock